Search
Edwards Lifesciences Corp
EWAdd to Watchlist
87.928USD
+0.978+1.12%
Close 06/23, 16:00（ET）Quotes delayed by 15 min
50.73BMarket Cap
46.70P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.12%
5 Days
-0.74%
1 Month
+2.50%
6 Months
+1.97%
Year to Date
+3.14%
1 Year
+16.74%
Key Figures
86.190Open
87.200High
3.00Volume
46.70P/E TTM
26.30P/E Dynamic
--Dividend TTM
0.00%Turnover Ratio
86.950Prev. Close
85.460Low
306.00Turnover
12.15P/E Static
4.91P/B
0.00%Div Yield TTM
8.15%ROA
88.28052wk High
-0.00Volume Ratio
4.17BNet Profit
577.00MShares
1.8830EPS TTM
0.87Beta
10.52%ROE
72.30052wk Low
2.00%Amplitude
78.01%Gross Margin
50.73BMarket Cap
0.97Reward/Risk
1.41%Risk Rate
TradingKey Stock Score of Edwards Lifesciences Corp
Currency: USD Updated: 2026-06-23Key Insights
Edwards Lifesciences Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 22 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 96.03.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Edwards Lifesciences Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
19°C
Very Low
Very High
Positive
Edwards Lifesciences Corp Highlights
StrengthsRisks
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.11% year-on-year.
Overvalued
The company’s latest PE is 46.18, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 539.60M shares, decreasing 2.34% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 1.02M shares of this stock.
Analyst Rating
Based on
34
analysts
Buy
Current Rating
96.026
Target Price
+11.81%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Edwards Lifesciences Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Edwards Lifesciences Corp Info
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Ticker SymbolEW
CompanyEdwards Lifesciences Corp
CEOZovighian (Bernard J)
Websitehttps://www.edwards.com
Related Instruments
+0.01%
0.00%
-0.03%
-0.04%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
-0.51%
0.00%
0.00%
0.00%
0.00%
+1.38%Popular Instruments
71.009
-1.936 (-2.65%)
296.050
+1.750 (+0.59%)
201.314
+1.274 (+0.64%)
3996.340
-114.410 (-2.78%)
680.465
+9.715 (+1.45%)
2020.000
+56.400 (+2.87%)
1092.599
+40.829 (+3.88%)
347.479
+1.349 (+0.39%)
62602.000
+161.300 (+0.26%)
383.700
+2.090 (+0.55%)
FAQs
What is the current price of Edwards Lifesciences Corp (EW)?
The current price of Edwards Lifesciences Corp (EW) is 86.96.
What is the symbol of Edwards Lifesciences Corp?
The ticker symbol of Edwards Lifesciences Corp is EW.
What is the 52-week high of Edwards Lifesciences Corp?
The 52-week high of Edwards Lifesciences Corp is 88.28.
What is the 52-week low of Edwards Lifesciences Corp?
The 52-week low of Edwards Lifesciences Corp is 72.30.
What is the market capitalization of Edwards Lifesciences Corp?
The market capitalization of Edwards Lifesciences Corp is 50.07B.
Is Edwards Lifesciences Corp (EW) currently rated as Buy, Hold, or Sell?
According to analysts, Edwards Lifesciences Corp (EW) has an overall rating of Buy, with a price target of 96.03.
What is the Earnings Per Share (EPS TTM) of Edwards Lifesciences Corp (EW)?
The Earnings Per Share (EPS TTM) of Edwards Lifesciences Corp (EW) is 1.84.
